

## **Tokai Pharmaceuticals Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 06-Jul-2015

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 16

[Return to Table of Contents](#)

# Tokai Pharmaceuticals Inc

## COMPANY OVERVIEW

Company Name	Tokai Pharmaceuticals Inc
Parent Company Name	Tokai Pharmaceuticals Inc
Website	<a href="http://www.tokaipharmaceuticals.com/">http://www.tokaipharmaceuticals.com/</a>
Country	US
Number of Drugs in Active Development	1
Number of Inactive Drugs	2
Number of Patents as Owner	11
Number of Patents as Third Party	0
Number of Deals	7
Key Indications	Hormone refractory prostate cancer, Pancreatic ductal adenocarcinoma, Prostate tumor, Breast tumor, Ovary tumor, Prostate hyperplasia, Alopecia, Anorexia nervosa, Cancer, Hirsutism
Key Target-based Actions	Cytochrome P450 17 inhibitor, Androgen receptor antagonist, Cytochrome P450 17A1 inhibitor, Androgen receptor modulator, Phosphoinositide 3-kinase inhibitor, Prostate specific antigen inhibitor, Topoisomerase II modulator, mTOR inhibitor
Key Technologies	Capsule formulation, Steroid, Drug combination, Oral formulation, Prodrug, Tablet formulation, Analytical method, Crystalline form, Drug screening, Formulation solid oral, Microparticle formulation

## COMPANY PROFILE

### SUMMARY

Tokai Pharmaceuticals, a privately-held biopharmaceutical company, focused on the development of treatments for prostate cancer.

### FINANCIAL

In September 2014, Tokai priced its initial public offering of 6.48 million shares of common stock at a public offering price of \$15 each. The underwriters were granted a 30-day option to purchase up to an additional 972,000 shares of common stock, at the public offering price. Tokai's common stock began trading on The NASDAQ Global Market under the ticker symbol 'TKAI'; later that month, the offering which resulted in gross proceeds of \$97.2 million was closed. By September 2014, the company had raised an additional gross proceeds of \$8.1 million, following the partial exercise of their option by the underwriters to purchase additional shares of 540,000.

In May 2013, the company raised \$35.5 million in a series E financing.

In September 2011, Tokai raised \$23 million in a series D3 financing.

## COMPANY FINANCIALS

### SHARE INFORMATION

Close Price (USD)	13.28
Change (USD)	-0.20 (-1.48%)
Previous Close Price (USD)	13.48

[Return to Table of Contents](#)



Volume	104,433
52-Week High (USD)	30.00
52-Week Low (USD)	9.67
Date	02-Jul-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	22,413,594
Current Market Capitalization	297,652,528
EPS (Date Reported)	-1.04082

## STOCK PERFORMANCE

Stock Performance



## MAJOR SHAREHOLDERS


Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Novartis AG	Corporation	Switzerland	4,609,414	20.57	-34,914	-0.01	16-Jun-2015
Fidelity Select Biotechnology Portfolio	Mutual Fund	United States	484,000	2.16	0	0	31-May-2015

[Return to Table of Contents](#)

Vanguard Total Stock Market Index Fund	Mutual Fund	United States	145,408	0.65	0	0	31-May-2015
Columbia Small Cap Growth Fund I	Mutual Fund	United States	131,500	0.59	-13,000	-0.09	30-Apr-2015
iShares Russell 2000 ETF	Mutual Fund	United States	93,798	0.42	-12,117	-0.11	31-May-2015
Fidelity Advisor Biotechnology Fund	Mutual Fund	United States	91,000	0.41	0	0	31-May-2015
JPMorgan U.S. Small Company Fund	Mutual Fund	United States	81,800	0.36	2,000	0.03	31-May-2015
iShares Russell 2000 Growth ETF	Mutual Fund	United States	38,539	0.17	-1,312	-0.03	31-May-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	37,351	0.17	2,937	0.09	31-May-2015
Fidelity Spartan Extended Market Index Fund	Mutual Fund	United States	22,549	0.1	0	0	31-May-2015
LifeSci Index Partners, LLC	Investment Advisor	United States	19,250	0.09	2,155	0.13	31-May-2015
BioShares Biotechnology Clinical Trials Fund	Mutual Fund	United States	19,250	0.09	2,155	0.13	31-May-2015
iShares Micro-Cap ETF	Mutual Fund	United States	16,280	0.07	-497	-0.03	31-May-2015
Morrison (Jodie Pope)	Individual Investor	United States	9,551	0.04	0	0	29-Jun-2015
Seasons Series Trust Small Cap Portfolio	Mutual Fund	United States	7,900	0.04	0	0	30-Apr-2015
Fidelity NASDAQ Composite Index Fund	Mutual Fund	United States	6,171	0.03	0	0	31-May-2015
Columbia Variable Portfolio - Small Company Growth Fund	Mutual Fund	United States	6,924	0.03	-76	-0.01	30-Apr-2015
Fidelity Spartan Total Market Index Fund	Mutual Fund	United States	5,465	0.02	0	0	31-May-2015
TIAA-CREF Small Cap Blend Index Fund	Mutual Fund	United States	6,036	0.03	0	0	30-Apr-2015
iShares Russell 2000 Value ETF	Mutual Fund	United States	5,102	0.02	-24	-0	31-May-2015

[Return to Table of Contents](#)





	2012	2013	2014		
Sales (USD M)	0	0	0		
Operating Income (USD M)	-9.649	-15.749	-23.462		
Net Income (USD M)	-9.683	-15.819	-23.296		

[Return to Table of Contents](#)

## Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2015 Q1	0	-13.3	-13.26
2014 Q4	0	-6.261	-6.208
2014 Q3	0	-6.424	-6.39
2014 Q2	0	-5.885	-5.851
2014 Q1	0	-4.892	-4.847
2013 Q4	0	-5.549	-5.54
2013 Q3	0	-3.365	-3.365
2013 Q2	0	-4.444	-4.524
2013 Q1	0	-2.391	-2.39

## BALANCE SHEET

### Assets (USD M)

	2012	2013	2014		
Cash & Short Term Investments	11.691	31.753	105.256		
Inventories - Total	0	0	0		
Current Assets - Total	11.926	32.178	107.511		
Property, Plant And Equipment - Net	0.016	0.029	0.033		
Other Assets - Total	0	0.03	0		
Total Assets	11.962	32.287	107.744		

### Liabilities (USD M)

	2012	2013	2014		
Accounts Payable	0.764	0.005	0.765		
Short Term Debt & Current Portion Of Long Term Debt	0	0	0		
Current Liabilities - Total	2.018	2.209	4.243		
Long Term Debt	0	0	0		
Other Liabilities	0	0	0		
Total Liabilities	2.018	2.209	4.243		

[Return to Table of Contents](#)



## Stockholders Equity (USD M)

	2012	2013	2014		
Minority Interest	0	0	0		
Preferred Stock	49.845	85.345	0		
Common Stock	0	0	0.022		
Treasury Stock	0	0	0		
Total Liabilities & Shareholders' Equity	11.962	32.287	107.744		

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-2	-2.09	-1.4
31-Dec-2016	-1.95	-1.91	-1.67
31-Dec-2017	-0.94	-0.94	0.68

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015			-44.66	0
31-Dec-2016			-52.16	0
31-Dec-2017			5.12	52.72

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	1	1	2
Genitourinary disease	1	1	2
Andrology	1	0	1
Gastrointestinal disease	1	0	1
Gynecology and obstetrics	0	1	1
Surgical procedure	0	1	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
No Development Reported	2

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	0	0	2	0	2
Drug - Early Research/Development	0	0	2	0	2
Drug - Development/Commercialization License	0	0	1	0	1
Technology - Delivery/Formulation	0	0	2	0	2

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	2	4

[Return to Table of Contents](#)



Andrology	2	4
Genitourinary disease	2	4

### Trials by Phase

Phase	Ongoing	All
Phase 3	1	1
Phase 2	1	2
Phase 1	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

### PATENTS \*

Indication	As Owner	As Third Party	Total
Endocrine disease	8	0	8
Gastrointestinal disease	1	0	1
Genitourinary disease	10	0	10
Growth disorder	4	0	4
Hematological disease	2	0	2
Andrology	10	0	10
Immune disorder	1	0	1
Psychiatric disorder	2	0	2
Musculoskeletal disease	2	0	2
Neoplasm	11	0	11
Neurological disease	1	0	1
Respiratory disease	1	0	1
Toxicity and intoxication	1	0	1
Gynecology and obstetrics	8	0	8

[Return to Table of Contents](#)



Dermatological disease	4	0	4
------------------------	---	---	---

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### galeterone

<b>Drug Name</b>	galeterone
<b>Key Synonyms</b>	galeterone
<b>Originator Company</b>	University of Maryland
<b>Active Companies</b>	University of Maryland, Tokai Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 3 Clinical
<b>Active Indications</b>	Hormone refractory prostate cancer, Prostate tumor, Pancreatic ductal adenocarcinoma
<b>Target-based Actions</b>	Cytochrome P450 17A1 inhibitor, Androgen receptor antagonist
<b>Other Actions</b>	Anticancer
<b>Technologies</b>	Oral formulation, Capsule formulation, Tablet formulation, Small molecule therapeutic, Steroid
<b>Last Change Date</b>	25-Jun-2015

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

